Italia markets closed

Adverum Biotechnologies, Inc. (0HA3.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,4900-0,1000 (-6,29%)
Alla chiusura: 03:32PM BST
Schermo intero
Chiusura precedente1,5900
Aperto1,4900
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,4900 - 1,4900
Intervallo di 52 settimane1,4900 - 1,4900
Volume1
Media VolumeN/D
Capitalizzazione1,196M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-1,5780
Prossima data utili02 nov 2022 - 07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Adverum Biotechnologies Reports Second Quarter 2022 Financial Results

    - Dosing first Phase 2 LUNA trial participant with ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) on track for the third quarter of 2022 and preliminary data anticipated throughout 2023 - Cash runway extended into 2025 to prioritize the clinical development of Ixo-vec and provide additional resources beyond anticipated one-year topline results of the Phase 2 LUNA trial REDWOOD CITY, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a cl

  • GlobeNewswire

    Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference

    REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022. The on-demand webcast corporate presentation may be

  • GlobeNewswire

    Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced a grant of stock options to a new employee. On August 1, 2022, Adverum granted a new employee a stock option to purchase 100,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that